stockrow
Friday 6 November 2026
Export SNYRQ’s income statement to Excel — free account
Synergy CHC Corp.
SNYRQ Healthcare Medical Distribution
Synergy CHC Corp.’s revenue for fiscal 2025 (year ended December 2025) was $30.4 million, down 12.8% from fiscal 2024.
- Revenue
- −32.8%
- EPS
- −330.0%
- Free cash flow
- −148.5%
- Total debt
- +7.08%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow SNYRQ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 38 | 43 | 35 | 30 | 28 | (7.5%) | 32 | 36 | — | +8.9% | |
| Gross margin, % | — | — | — | — | — | — | 34.62 | 74.99 | 67.87 | 66.83 | 65.37 | +32.2 pt | ||||||
| EBT | — | — | — | — | — | — | (33) | 7 | 2 | (12) | (16) | (27.9%) | ||||||
| EBT margin, % | — | — | — | — | — | — | (84.87) | 15.37 | 6.39 | (40.23) | (56.57) | +44.6 pt | ||||||
| Net income | — | — | — | — | — | — | (33) | 6 | 2 | (12) | (16) | (27.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 5.08 | 5.80 | 4.59 | 3.12 | 2.45 | (15.0%) | |||||
| Earnings | — | — | — | — | — | — | (4.32) | 0.86 | 0.28 | (1.27) | (1.40) | (33.5%) | ||||||
| Cash flow | — | — | — | — | — | — | (1.12) | 0.06 | (0.63) | (0.27) | (0.34) | (38.0%) | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (1.12) | 0.06 | (0.63) | (0.27) | (0.34) | (38.0%) | ||||||
| Book value | — | — | — | — | — | — | (4.44) | (3.70) | (2.19) | (2.38) | (2.25) | (18.8%) | ||||||
| Shares, m | — | — | — | — | — | — | 8 | 7 | 8 | 10 | 10 | +8.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.02 | 0.02 | 15.85 | 0.00 | 0.00 | 4.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 0.96 | 0.60 | 0.00 | 0.4 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.81 | 1.50 | 1.33 | 0.89 | 0.9 | ||||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 16.16 | (10.91) | (15.67) | (6.49) | (2.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (8) | 0 | (5) | (3) | (4) | (32.6%) | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | (8) | 0 | (5) | (3) | (4) | (32.6%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (12) | (2) | (1) | 2 | (1) | n/m | |||||
| Net debt | — | — | — | — | — | — | 19 | 25 | 19 | 22 | 25 | +5.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (34) | (27) | (17) | (23) | (25) | (11.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | 41.19 | 14.87 | (93.11) | (142.75) | (93.1) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 152.93 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (20.84) | (9.67) | 62.08 | 76.92 | +62.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 25 | 21 | 28 | — | +5.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 1.71 | 1.66 | 1.09 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026
Synergy CHC Corp. vs peers in Medical Distribution (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HSIC Henry Schein, Inc. | $9.4B | 22.8× | 21.3× | +3.95% (above 0%: growing) | +34.81% (above 0%: growing) | −7.09% (below 0%: shrinking) | 31.84% | 5.56% | Compare |
| AHG Akso Health Group Sponsored ADR | $1.1B | — (loss-making) | — (loss-making) | +263.89% (above 0%: growing) | n/m | −12,975.04% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FOCL FocalTherics | $159.3M | — (loss-making) | — (loss-making) | +38.85% (above 0%: growing) | n/m | +21.49% (above 0%: growing) | 55.59% | (60.83%) | Compare |
| COSM Cosmos Health Inc. | $29.2M | — (loss-making) | — (loss-making) | +28.76% (above 0%: growing) | n/m | +9.39% (above 0%: growing) | 7.96% | (15.41%) | Compare |
| ACH Accendra Health, Inc. | $23.0M | — (loss-making) | — (loss-making) | −10.07% (below 0%: shrinking) | n/m | −1,624.82% (below 0%: shrinking) | 42.95% | (5.73%) | Compare |
| YI 111, Inc. Sponsored ADR | $15.5M | — (loss-making) | — (loss-making) | −29.61% (below 0%: shrinking) | n/m | −185.70% (below 0%: shrinking) | 5.33% | (0.85%) | Compare |
| MEDS DataMeds AI, Inc | $5.5M | — (loss-making) | — | −77.15% (below 0%: shrinking) | n/m | −41.85% (below 0%: shrinking) | 10.24% | (412.67%) | Compare |
| HKPD Cellyan Biotechnology Co., Ltd | $3.4M | — | — | — | — | −90.45% (below 0%: shrinking) | — | — | Compare |
| SNYRQ Synergy CHC Corp. | $1.3M | — (loss-making) | 1.6× | −32.77% (below 0%: shrinking) | n/m | −148.51% (below 0%: shrinking) | 72.29% | (10.32%) | |
| Median of peers | $26.1M | — | — | +3.95% | — | −66.15% | 10.24% | (5.73%) |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.14m | 1.14m | 0.00 |
| 2024 | 1.32k | 1.32k | 0.00 |
| 2023 | 520.00k | 520.00k | 0.00 |
Ownership
Directors and executive officers, together
32.90%
Jack Ross
32.20%
Gowan Private Equity Inc.
24.70%
Knight Therapeutics International S.A.
12.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement